Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients

被引:19
作者
Wu, Sheng-nan
Gao, Rui
Xing, Qing-he
Li, Hua-fang
Shen, Yi-feng
Gu, Niu-fan
Feng, Guo-yin
He, Lin [1 ]
机构
[1] Shanghai Jiao Tong Univ, Bio X Life Sci Res Ctr, Shanghai 200030, Peoples R China
[2] Chinese Acad Sci, Inst Nutr Sci, SIBS, Shanghai 200031, Peoples R China
[3] Shanghai Inst Mental Hlth, Shanghai 200030, Peoples R China
[4] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Hypertens, Shanghai 200025, Peoples R China
关键词
dopamine receptors; basal ganglia disease; polymorphism; chlorpromazine; schizophrenia;
D O I
10.1111/j.1745-7254.2006.00355.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor. Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression. In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients. Methods: We identified seven SNP(single nucleotidepolymorphism) (-141Cins > del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks. The alleles of all loci were determined by PCR (polymerase chain reaction). Results: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study. No statistical significance was found in the allele distribution of -141Cins > del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups. Conclusion: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia. Our results confirmed a previous study on the relationship between DRD2 and EPS in
引用
收藏
页码:966 / 970
页数:5
相关论文
共 30 条
[1]   A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia [J].
Arinami, T ;
Gao, M ;
Hamaguchi, H ;
Toru, M .
HUMAN MOLECULAR GENETICS, 1997, 6 (04) :577-582
[2]   Motor and mental aspects of extrapyramidal syndromes [J].
Casey, DE .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :105-114
[3]   Association of TaqI a polymorphism of dopamine D-2 receptor gene and tardive dyskinesia in schizophrenia [J].
Chen, CH ;
Wei, FC ;
Koong, FJ ;
Hsiao, KJ .
BIOLOGICAL PSYCHIATRY, 1997, 41 (07) :827-829
[4]   Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants [J].
Cravchik, A ;
Sibley, DR ;
Gejman, PV .
PHARMACOGENETICS, 1999, 9 (01) :17-23
[5]   The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia [J].
Dubertret, C ;
Gouya, L ;
Hanoun, N ;
Deybach, JC ;
Adès, J ;
Hamon, M ;
Gorwood, P .
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) :75-85
[6]   VARIABILITY IN D-2-DOPAMINE RECEPTOR DENSITY AND AFFINITY - A PET STUDY WITH [C-11] RACLOPRIDE IN MAN [J].
FARDE, L ;
HALL, H ;
PAULI, S ;
HALLDIN, C .
SYNAPSE, 1995, 20 (03) :200-208
[7]   A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients [J].
Farde, L ;
Suhara, T ;
Nyberg, S ;
Karlsson, P ;
Nakashima, Y ;
Hietala, J ;
Halldin, C .
PSYCHOPHARMACOLOGY, 1997, 133 (04) :396-404
[8]  
Farde L, 1993, Psychopharmacol Ser, V10, P94
[9]   D-2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: A pilot study with sertindole in healthy subjects [J].
Farde, L ;
Mack, RJ ;
Nyberg, S ;
Halldin, C .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 :S3-S7
[10]   The NIMH perspective: Next steps in schizophrenia research [J].
Hyman, SE .
BIOLOGICAL PSYCHIATRY, 2000, 47 (01) :1-7